Orla M Neylon1, Timothy C Skinner2, Michele A O'Connell1, Fergus J Cameron1. 1. Department of Endocrinology, Murdoch Childrens Research Institute and The Royal Children's Hospital, Parkville, Australia. 2. School of Psychological and Clinical Sciences, Charles Darwin University, Darwin, Australia.
Abstract
BACKGROUND AND OBJECTIVE: Controversy exists regarding which individuals will benefit most from commencement of diabetes technologies such as continuous subcutaneous insulin infusion (CSII) or continuous glucose monitoring systems (CGMS), such as 'real-time' sensor-augmented pumping (SAP). Because higher usage correlates with haemoglobin A1c (HbA1c) achieved, we aimed to predict future usage of technologies using a questionnaire-based tool. SUBJECTS: The tool was distributed to two groups of youth with type 1 diabetes; group A (n = 50; mean age 12 ± 2.5 yr) which subsequently commenced 'real-time' CGMS and group B (n = 47; mean age 13 ± 3 yr) which commenced CSII utilisation. METHODS: For the CGMS group, recommended usage was ≥5 days (70%) per week [≥70% = high usage (HU); <70% = low usage (LU)], assessed at 3 months. In the CSII group, HU was quantified as entering ≥5 blood sugars per day to the pump and LU as <5 blood sugars per day, at 6 months from initiation. Binary logistic regression with forward stepwise conditional was used to utilise tool scales and calculate an applied formula. RESULTS: Of the CGMS group, using gender, baseline HbA1c, and two subscales of the tool generated a formula which predicted both high and low usage with 92% accuracy. Twelve (24%) showed HU vs. 38 who exhibited LU at 3 months. Of the CSII group, 32 (68%) exhibited HU vs. 15 who exhibited LU at 6 months. Four tool items plus gender predicted HU/LU with 95% accuracy. CONCLUSIONS: This pilot study resulted in successful prediction of individuals who will and those who will not go on to show recommended usage of CSII and CGMS.
BACKGROUND AND OBJECTIVE: Controversy exists regarding which individuals will benefit most from commencement of diabetes technologies such as continuous subcutaneous insulin infusion (CSII) or continuous glucose monitoring systems (CGMS), such as 'real-time' sensor-augmented pumping (SAP). Because higher usage correlates with haemoglobin A1c (HbA1c) achieved, we aimed to predict future usage of technologies using a questionnaire-based tool. SUBJECTS: The tool was distributed to two groups of youth with type 1 diabetes; group A (n = 50; mean age 12 ± 2.5 yr) which subsequently commenced 'real-time' CGMS and group B (n = 47; mean age 13 ± 3 yr) which commenced CSII utilisation. METHODS: For the CGMS group, recommended usage was ≥5 days (70%) per week [≥70% = high usage (HU); <70% = low usage (LU)], assessed at 3 months. In the CSII group, HU was quantified as entering ≥5 blood sugars per day to the pump and LU as <5 blood sugars per day, at 6 months from initiation. Binary logistic regression with forward stepwise conditional was used to utilise tool scales and calculate an applied formula. RESULTS: Of the CGMS group, using gender, baseline HbA1c, and two subscales of the tool generated a formula which predicted both high and low usage with 92% accuracy. Twelve (24%) showed HU vs. 38 who exhibited LU at 3 months. Of the CSII group, 32 (68%) exhibited HU vs. 15 who exhibited LU at 6 months. Four tool items plus gender predicted HU/LU with 95% accuracy. CONCLUSIONS: This pilot study resulted in successful prediction of individuals who will and those who will not go on to show recommended usage of CSII and CGMS.
Authors: Gregory P Forlenza; Tim Vigers; Cari Berget; Laurel H Messer; Rayhan A Lal; Marina Basina; David M Maahs; Korey Hood; Bruce Buckingham; Darrell M Wilson; R Paul Wadwa; Kimberly A Driscoll; Laura Pyle Journal: Diabetes Technol Ther Date: 2021-12-01 Impact factor: 7.337
Authors: Laurel H Messer; Peter Calhoun; Bruce Buckingham; Darrell M Wilson; Irene Hramiak; Trang T Ly; Marsha Driscoll; Paula Clinton; David M Maahs Journal: Pediatr Diabetes Date: 2016-04-29 Impact factor: 4.866
Authors: Jason Van Allen; Amy E Noser; Andrew K Littlefield; Paige L Seegan; Mark Clements; Susana R Patton Journal: J Pediatr Psychol Date: 2018-03-01